Hi DT

From conversations with others I believe that prior to receiving any drugs from reputable (or otherwise) suppliers there is a lot of research and discussion by Dr Freeman. An example of this is with mesochem, Dr Freeman has been developing this supply chain integrity since February this 2015. Firstly with Sofosbruvir, then Ledipravir and recently daclatsavir. Therefore I believe it has reached the point where folk can be reasonably confident with this particular source and there are other being developed if the mesochem door closes. Gilead have done an incredible job promoting the harvoni (sofosbruvir/ledipravir) option and it is a game changer no doubt. But out of reach to most people at this stage due to price and I’m sure that Gilead are aware that as soon as sofosbruvir becomes generic, the leaves will fall of the money tree. So I’m wondering how Gilead will restrict access to the generics on the sub continent, I’m sure they’re looking at this strategically. Em